Flagship unwraps new AI biotech that looks to predict variants before they’re here
While Moderna is testing Omicron-specific boosters for this fall, its investor Flagship Pioneering is building a biotech that says it uses AI to predict virus variants prior to outbreaks.
Apriori Bio, derived from the Latin phrase a priori that translates to “from the previous,” emerged from stealth Monday with $50 million. The Cambridge, MA-based biotech was founded in 2020 in the midst of the Covid-19 pandemic, though Apriori CEO Lovisa Afzelius says the biotech will tackle multiple “ultra-dynamic” viruses outside of SARS-CoV-2, including the flu virus and HIV.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
